Drug Trial Radar · NCT07100080
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
661
Planned (sponsor's estimate)
Start
Nov 5, 2025
Primary completion
Dec 15, 2028
Study completion Nov 15, 2030
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Aug 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study of Izalontamab Brengitecan (BMS-986507) versus platinum-based chemotherapy with or without Amivantamab for EGFR-mutated non-small cell lung cancer after failure of EGFR TKI therapy
Conditions
- Non-Small Cell Lung Cancer
Interventions
Iza-brenDrug
Specified dose on specified days
CarboplatinDrug
Specified dose on specified days
CisplatinDrug
Specified dose on specified days
PemetrexedDrug
Specified dose on specified days
AmivantamabDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase 3 Dose (RP3D) of BMS-986507Time frame: Approximately 3 months after the first dose
- Progression-Free Survival (PFS) Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR)Time frame: Up to 3 years
Locations
187 sites in 25 countries. Site status is shown where the registry gives one.
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care building
Irvine, California · Recruiting
University of California, Irvine (UCI) Health - UC Irvine Medical Center
Orange, California · Recruiting
Shaw Cancer Center
Edwards, Colorado · Recruiting
Local Institution - 0085
Gainesville, Florida · Withdrawn
Local Institution - 0142
Pembroke Pines, Florida · Not yet recruiting
Piedmont Healthcare
Atlanta, Georgia · Recruiting
John B Amos Cancer Center
Columbus, Georgia · Recruiting
Rush University Medical Center
Chicago, Illinois · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Renown Regional Medical Center
Reno, Nevada · Recruiting
Perlmutter Cancer Center at NYU Langone Hospital - Long Island
Mineola, New York · Recruiting
NYU Langone Health
New York, New York · Recruiting
Weill Cornell Medical College
New York, New York · Recruiting
Rochester General Hospital Infectious Disease
Rochester, New York · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C
Columbus, Ohio · Recruiting
Providence Cancer Institute Franz Clinic
Portland, Oregon · Recruiting
Providence St. Vincent Medical Center
Portland, Oregon · Recruiting
Oregon Health and Science University
Portland, Oregon · Recruiting
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
West Penn Allegheny Health
Pittsburgh, Pennsylvania · Recruiting
Local Institution - 0268
Chattanooga, Tennessee · Withdrawn
Tennessee Oncology
Nashville, Tennessee · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Local Institution - 0173
San Antonio, Texas · Not yet recruiting
University of Virginia Health System
Charlottesville, Virginia · Recruiting
Virginia Commonwealth University (Vcu)
Richmond, Virginia · Recruiting
Hospital Privado Universitario de Córdoba
Córdoba, Argentina · Recruiting
Instituto Alexander Fleming
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Hospital Italiano de Buenos Aires
ABB, Buenos Aires F.D., Argentina · Recruiting
Local Institution - 0280
Wilrijk, Antwerpen, Belgium · Not yet recruiting
Local Institution - 0161
Auderghem, Bruxelles-Capitale, Région de, Belgium · Not yet recruiting
Local Institution - 0022
Yvoir, Namur, Belgium · Not yet recruiting
Local Institution - 0023
Ghent, Oost-Vlaanderen, Belgium · Not yet recruiting
Local Institution - 0024
Sint-Niklaas, Oost-Vlaanderen, Belgium · Not yet recruiting
Arthur J. E. Child Comprehensive Cancer Centre
Calgary, Alberta, Canada · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Local Institution - 0184
Chicoutimi, Quebec, Canada · Not yet recruiting
Local Institution - 0185
Montreal, Quebec, Canada · Withdrawn
Showing 40 of 187 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.